A clinical study of the association of antipsychotics with hyperlipidemia

Schizophrenia Research

Volumn 92, Issue 1-3, 2007, Pages 95-102

  de Leon, Jose ^a,b,c   Susce, Margaret T ^a,b   Johnson, Maria ^a,b   Hardin, Mike ^a,b   Pointer, Lana ^a,b   Ruaño, Gualberto ^d   Windemuth, Andreas ^d   Diaz, Francisco J ^e  

^a Eastern State Hospital   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF GRANADA   (Spain)

^d Genomas Inc   (United States)

^e UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Antipsychotics; Cholesterol; Effect sizes; Lipids; Metabolic syndrome; Obesity; Olanzapine; Quetiapine; Relative percentiles; Triglycerides

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; ARTICLE; BODY FAT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DRUG MECHANISM; EFFECT SIZE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; METABOLIC SYNDROME X; PSYCHOTIC DISORDERS; RISK FACTORS; TRIGLYCERIDES;

EID: 34147150577     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.01.015     Document Type: Article

References (19)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., and Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 (1999) 1686-1696
2. Baptista T., and Kin N.M.K.N.Y. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35 (2002) 205-219
3. Baldessarini R.J. Chemotherapy in Psychiatry (1985), Harvard University Press, Cambridge, MA
4. Brown S., Birtwistle J., Roe L., and Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 29 (1999) 697-701
5. Cohen J. A power primer. Psychol. Bull. 112 (1992) 155-159
6. Henderson D.C., Copeland P.M., Borba C.P., Daley T.B., Nguyen D.D., Cagliero E., Evins A.E., Zhang H., Hayden D.L., Freudenreich O., Cather C., Schoenfeld D.A., and Goff D.C. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J. Clin. Psychiatry 67 (2006) 789-797
7. Kraemer H.C., and Kupfer D.J. Size of treatment effects and their importance to clinical research and practice (review). Biol. Psychiatry 59 (2005) 990-996
8. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S.E., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsaio J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
9. Markham-Abedi C., and de Leon J. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report (letter). J. Clin. Psychiatry 67 (2006) 1473-1474
10. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., Davis J.M., Kane J.M., Lieberman J.A., Schooler N.R., Covell N., Stroup S., Weissman E.M., Wirshing D.A., Hall C.S., Pogach L., Pi-Sunyer X., Bigger Jr. J.T., Friedman A., Kleinberg D., Yevich S.J., Davis B., and Shon S. Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry 161 (2004) 334-1349
11. Meyer J.M. Novel antipsychotics and severe hyperlipidemia. J. Clin. Psychopharmacol. 21 (2001) 369-373
12. Meyer J.M., and Koro C.E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 70 (2004) 1-17
13. Muñoz A., and Xu J. Models for the incubation of AIDS and variations according to age and period. Stat. Med. 15 (1996) 2459-2473
14. Panz V.R., Raal F.J., Paiker J., Immelman R., and Miles H. Performance of the CardioChek PA and Cholestech LDX point-of-care analysers compared to clinical diagnostic laboratory methods for the measurement of lipids. Cardiovasc. J. South. Afr. 16 (2005) 112-117
15. Ritchie J.D., Miller C.K., and Smiciklas-Wright H. Tanita foot-to-foot bioelectrical impedance analysis system validated in older adults. J. Am. Diet Assoc. 105 (2005) 1617-1619
16. Ruaño, G., Goethe, J.W., Caley, C., Woolley, S., Holford, T.R., Kocherla, M., Windemuth, A., Leon, J.D., in press. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol. Psychiatry [Electronic publication ahead of print 2 Jan 2007].
17. Susce M.T., Villanueva N., Diaz F.J., and de Leon J. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J. Clin. Psychiatry 66 (2005) 167-173
18. Woodward M. Epidemiology: Study Design and Data Analysis (1999), Chapman & Hall/CRC, Boca Raton
19. Woods S.W. Chlorpromazine equivalent dose for the newer atypical antipsychotics. J. Clin. Psychiatry 64 (2003) 663-667